Y-320,288250-47-5

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Y-320

CAS No. : 288250-47-5

MCE 国际站：Y-320

产品活性：Y-320 是一种口服有效的苯吡唑苯胺免疫调节剂。Y-320 抑制 IL-15 刺激的 CD4 T 细胞产生 IL-17, 其 IC₅₀ 值为 20-60 nM。Y-320 增强 G418 对 TP53、DMD和COL17A1 PTC 的读入，增加细胞蛋白质水平和蛋白质合成。Y-320 与低剂量 Paclitaxel (HY-B0015) 通过诱导 G2/M 期阻滞和细胞凋亡 (apoptosis) 显著致敏多药耐药性 (MDR) 肿瘤。Y-320 可用于类风湿关节炎 (RA) 和肿瘤的研究。

研究领域：Immunology/Inflammation  |  Apoptosis

作用靶点：Interleukin Related  |  Apoptosis

In Vitro: Y-320 (0-100 nM; 48 h) inhibits IL-17 production by murine and human CD4 T Cells stimulated with IL-15 with IC₅₀ values of 25.7, 52.4 and 57.4 nM for murine CD4 T cells, murine Th17 cells and human CD4 T cells, respectively.
Y-320 (0-100 nM; 48 h) inhibits phosphorylation of JAK1/JAK3 in murine CD4 T cells stimulated with IL-15/CXCL12/anti-CD3 mAb.
Y-320 (0.25-2 μM; 48 h) enhances PTC readthrough by G418 in different cell lines.
Y-320 (0-2 μM; 48 h; HDQ-P1 cells) increases cellular protein levels and ribosome biogenesis in a concentration-dependent manner.
Y-320 (0-2 μM; 48 h; Tsc2^-/- cells) causes a small decrease in phospho-S6K combination with G418 (100 μM).
Y-320 (1 μM; 48 h; HDQ-P1 cells) up-regulates CXC chemokine expression including CXCL10, CXCL8, and CXCL2.
Y-320 (500 nM; 72 h) reverses the resistance to paclitaxel in MDR cancer cells. Y-320 has the reversal index (RI) combined with Paclitaxel (0-1000 nM) are 5.5 (Bads-200), 9.4 (Bats-72) and 1.7 (Huh7-TS-48).
Y-320 (500 nM; 72 h; Bads-200 cells) enhances Paclitaxel-induced G2/M arrest and enhances Paclitaxel-induced (500 nM) tumor cell apoptosis.
Y-320 (0-20 μM; 72 h; Bads-200 cells) is a substrate of P-gp reverses MDR by inhibiting P-gp function.

In Vivo: Y-320 (0-3 mg/kg; p.o.; daily, for 42 d) ameliorates collagen-induced arthritis (CIA) in DBA/1J mice with a reduction of IL-17 mRNA in arthritic joints.
Y-320 (5 mg/kg; i.v.; every three days, for 18 d; Homozygous nude athymic mice with Bats-72 xenograft) sensitizes MDR xenograft tumor to Paclitaxel in vivo.

相关产品：Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Immunology/Inflammation Compound Library  |  Anti-Cancer Compound Library  |  Differentiation Inducing Compound Library  |  Orally Active Compound Library  |  Angiogenesis-Related Compound Library  |  Targeted Diversity Library  |  Heterocyclic Compound Library  |  Autoimmune Disease Compound Library  |  Highly Selective Inhibitors Library  |  Highly Selective Activators Library  |  Cytokine Inhibitors Library  |  Cell Death Library  |  MG-132  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  LY294002  |  Tamoxifen  |  Paclitaxel  |  Y-27632  |  Acetylcysteine  |  Angiotensin II human  |  2-Deoxy-D-glucose  |  Staurosporine  |  SB-431542  |  Actinomycin D  |  Deferoxamine mesylate  |  Bortezomib  |  5-Fluorouracil  |  Trametinib  |  Sorafenib  |  Oxaliplatin  |  Gemcitabine  |  Temozolomide  |  Rotenone  |  Mdivi-1  |  Elesclomol  |  Ruxolitinib  |  Decitabine  |  SP600125  |  MK-2206 dihydrochloride  |  Etoposide  |  Resatorvid

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds